20-Epi	O
analogues	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
binding	O
to	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-DNA
(	O
Waf1	B-DNA
,	O
Cip1	B-DNA
)	O
,	O
a	O
key	O
VDR	B-DNA
target	I-DNA
gene	I-DNA
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B-protein
interacting	O
proteins	O
:	O
RXR	B-protein
,	O
GRIP-1	B-protein
,	O
and	O
DRIP205	B-protein
,	O
a	O
subunit	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B-protein
with	O
RXR	B-protein
or	O
GRIP-1	B-protein
,	O
the	O
differentiation	O
dose-response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand-dependent	O
recruitment	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
to	O
VDR	B-protein
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell-free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B-protein
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

24	NULL
,	NULL
Issue	NULL
of	NULL
June	NULL
11	NULL
,	NULL
pp	NULL
.	NULL

16838-16845	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
20-Epi	NULL
Analogues	NULL
of	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
,	NULL
Are	NULL
Highly	NULL
Potent	NULL
Inducers	NULL
of	NULL
DRIP	NULL
Coactivator	NULL
Complex	NULL
Binding	NULL
to	NULL
the	NULL
Vitamin	NULL
D	NULL
;	NULL
,	NULL
Receptor*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
19	NULL
,	NULL
1999	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
March	NULL
31	NULL
,	NULL
1999	NULL
)	NULL
Wen	NULL
Yang	NULL
?	NULL

#	NULL
and	NULL
Leonard	NULL
P.	NULL
From	NULL
the	NULL
Cell	NULL
Biology	NULL
Program	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
stimulation	NULL
of	NULL
bone	NULL
growth	NULL
,	NULL
mineralization	NULL
,	NULL
and	NULL
intestinal	NULL
calcium	NULL
and	NULL
phosphate	NULL
absorption	NULL
;	NULL
it	NULL
also	NULL
acts	NULL
as	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
cellular	NULL
proliferation	NULL
.	NULL

Several	NULL
new	NULL
,	NULL
clinically	NULL
relevant	NULL
compounds	NULL
dissociate	NULL
antiproliferative	NULL
and	NULL
calcemic	NULL
activities	NULL
of	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
but	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
this	NULL
has	NULL
not	NULL
been	NULL
clearly	NULL
eluci-dated	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
the	NULL
potency	NULL
of	NULL
one	NULL
class	NULL
of	NULL
compounds	NULL
,	NULL
20-epi	NULL
analogues	NULL
,	NULL
to	NULL
induce	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
is	NULL
because	NULL
of	NULL
direct	NULL
molecular	NULL
effects	NULL
on	NULL
vitamin	NULL
D	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
.	NULL

We	NULL
report	NULL
that	NULL
two	NULL
20-epi	NULL
analogues	NULL
,	NULL
MC1627	NULL
and	NULL
MC1288	NULL
,	NULL
induced	NULL
differentiation	NULL
and	NULL
transcription	NULL
of	NULL
p21	NULL
``	NULL
**	NULL
``	NULL
``	NULL
,	NULL
a	NULL
key	NULL
VDR	NULL
target	NULL
gene	NULL
involved	NULL
in	NULL
growth	NULL
inhibition	NULL
,	NULL
at	NULL
a	NULL
concentration	NULL
100-fold	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
,	NULL
.	NULL

We	NULL
compared	NULL
this	NULL
sensitivity	NULL
to	NULL
analogue	NULL
effects	NULL
on	NULL
VDR	NULL
interacting	NULL
pro-teins	NULL
:	NULL
RXR	NULL
,	NULL
GRIP-1	NULL
,	NULL
and	NULL
DRIP205	NULL
,	NULL
a	NULL
subunit	NULL
of	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
.	NULL

Compared	NULL
with	NULL
the	NULL
interaction	NULL
of	NULL
VDR	NULL
with	NULL
RXR	NULL
or	NULL
GRIP-1	NULL
,	NULL
the	NULL
differentiation	NULL
dose-response	NULL
most	NULL
closely	NULL
correlated	NULL
to	NULL
the	NULL
ligand-dependent	NULL
recruitment	NULL
of	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
to	NULL
VDR	NULL
and	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
receptor	NULL
to	NULL
activate	NULL
transcription	NULL
in	NULL
a	NULL
cell-free	NULL
system	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
compelling	NULL
links	NULL
between	NULL
the	NULL
efficiency	NULL
of	NULL
the	NULL
20-epi	NULL
analogue	NULL
in	NULL
inducing	NULL
VDR/DRIP	NULL
interactions	NULL
,	NULL
transactivation	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
its	NULL
enhanced	NULL
ability	NULL
to	NULL
induce	NULL
cellular	NULL
differentiation	NULL
.	NULL

In	NULL
the	NULL
early	NULL
part	NULL
of	NULL
this	NULL
century	NULL
,	NULL
vitamin	NULL
D	NULL
;	NULL
was	NULL
discovered	NULL
as	NULL
a	NULL
fat-soluble	NULL
substance	NULL
with	NULL
antirachitic	NULL
activity	NULL
(	NULL
1	NULL
)	NULL
.	NULL

It	NULL
was	NULL
subsequently	NULL
found	NULL
that	NULL
vitamin	NULL
D	NULL
,	NULL
must	NULL
be	NULL
metabolized	NULL
to	NULL
an	NULL
active	NULL
hormonal	NULL
form	NULL
before	NULL
it	NULL
can	NULL
elicit	NULL
its	NULL
biological	NULL
effects	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Upon	NULL
exposure	NULL
to	NULL
UV	NULL
light	NULL
,	NULL
vitamin	NULL
D	NULL
;	NULL
is	NULL
synthesized	NULL
,	NULL
converted	NULL
in	NULL
the	NULL
liver	NULL
to	NULL
25-hydroxyvitamin	NULL
D	NULL
;	NULL
,	NULL
and	NULL
hydroxylated	NULL
in	NULL
the	NULL
kidney	NULL
to	NULL
its	NULL
active	NULL
form	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D3	NULL
(	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
)	NULL
.1	NULL
Functions	NULL
of	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
include	NULL
the	NULL
stimulation	NULL
of	NULL
bone	NULL
growth	NULL
and	NULL
mineralization	NULL
and	NULL
the	NULL
increase	NULL
intes-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
DK45460	NULL
(	NULL
to	NULL
L.	NULL
P.	NULL
F.	NULL
)	NULL
and	NULL
CAO8748	NULL
(	NULL
Core	NULL
Center	NULL
Grant	NULL
)	NULL
to	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
}	NULL

Supported	NULL
by	NULL
the	NULL
Endocrine	NULL
Research	NULL
Training	NULL
Program	NULL
(	NULL
DK07313	NULL
)	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Cell	NULL
Biology	NULL
Program	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
1275	NULL
York	NULL
Ave.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
212-689-2976	NULL
;	NULL
Fax	NULL
:	NULL
212-717-3298	NULL
;	NULL
E-mail	NULL
:	NULL
l-freedman	NULL
@	NULL
ski.mskec.org	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
VDR	NULL
,	NULL
VDR	NULL
,	NULL
vitamin	NULL
D	NULL
receptor	NULL
;	NULL
AF-2	NULL
,	NULL
activation	NULL
function-2	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
VDRE	NULL
,	NULL
vitamin	NULL
D-responsive	NULL
element	NULL
;	NULL
LBD	NULL
,	NULL
ligand	NULL
binding	NULL
domain	NULL
;	NULL
DRIP	NULL
,	NULL
VDR	NULL
interacting	NULL
protein	NULL
;	NULL
DBP	NULL
,	NULL
vitamin	NULL
D	NULL
binding	NULL
protein	NULL
;	NULL
OCT	NULL
,	NULL
1,25-dihydroxy-22-oxa-vitamin	NULL
D	NULL
,	NULL
;	NULL
FACS	NULL
,	NULL
fluores-	NULL
16838	NULL
tinal	NULL
calcium	NULL
and	NULL
phosphate	NULL
absorption	NULL
.	NULL

In	NULL
recent	NULL
years	NULL
,	NULL
accumulating	NULL
evidence	NULL
points	NULL
to	NULL
the	NULL
involvement	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
a	NULL
number	NULL
of	NULL
diverse	NULL
biological	NULL
processes	NULL
,	NULL
including	NULL
the	NULL
regulation	NULL
of	NULL
cellular	NULL
proliferation	NULL
and	NULL
differentiation	NULL
,	NULL
immunosup-pression	NULL
,	NULL
and	NULL
hormone	NULL
secretion	NULL
.	NULL

Similar	NULL
to	NULL
other	NULL
steroid	NULL
hormones	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
acts	NULL
by	NULL
binding	NULL
stereospecifically	NULL
to	NULL
a	NULL
high	NULL
affinity	NULL
,	NULL
low	NULL
capacity	NULL
intracel-lular	NULL
receptor	NULL
protein	NULL
,	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
(	NULL
3	NULL
)	NULL
.	NULL

VDR	NULL
is	NULL
a	NULL
48-kDa	NULL
protein	NULL
and	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
steroid/nuclear	NULL
receptor	NULL
superfamily	NULL
that	NULL
contains	NULL
discrete	NULL
functional	NULL
domains	NULL
for	NULL
ligand	NULL
binding	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
transcriptional	NULL
activation	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Transactivation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
requires	NULL
a	NULL
carboxyl-termi-nal	NULL
a-helical	NULL
region	NULL
,	NULL
termed	NULL
activation	NULL
function-2	NULL
(	NULL
AF-2	NULL
)	NULL
,	NULL
that	NULL
forms	NULL
part	NULL
of	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Upon	NULL
binding	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
VDR	NULL
dimerizes	NULL
with	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
(	NULL
RXR	NULL
)	NULL
to	NULL
enable	NULL
high	NULL
affinity	NULL
interactions	NULL
with	NULL
a	NULL
specific	NULL
vitamin	NULL
D-responsive	NULL
element	NULL
(	NULL
VDRE	NULL
)	NULL
located	NULL
in	NULL
5'-flanking	NULL
regions	NULL
of	NULL
target	NULL
genes	NULL
.	NULL

Binding	NULL
of	NULL
VDR/RXR	NULL
results	NULL
in	NULL
either	NULL
the	NULL
up-	NULL
or	NULL
down-regulation	NULL
of	NULL
transcription	NULL
.	NULL

Recent	NULL
evidence	NULL
has	NULL
suggested	NULL
that	NULL
VDR	NULL
exerts	NULL
its	NULL
transcriptional	NULL
activity	NULL
,	NULL
at	NULL
least	NULL
partially	NULL
,	NULL
via	NULL
direct	NULL
interactions	NULL
with	NULL
TFIIB	NULL
and	NULL
TFIIA	NULL
,	NULL
proteins	NULL
of	NULL
the	NULL
preinitiation	NULL
complex	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
an	NULL
intermediary	NULL
class	NULL
of	NULL
proteins	NULL
called	NULL
coactivators	NULL
was	NULL
discovered	NULL
that	NULL
may	NULL
facilitate	NULL
the	NULL
interaction	NULL
between	NULL
nuclear	NULL
receptors	NULL
and	NULL
basal	NULL
transcription	NULL
machinery	NULL
.	NULL

To	NULL
date	NULL
,	NULL
several	NULL
coactivators	NULL
have	NULL
been	NULL
identified	NULL
by	NULL
biochemical	NULL
interaction	NULL
or	NULL
yeast	NULL
two-hybrid	NULL
assays	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

26	NULL
)	NULL
.	NULL

These	NULL
identified	NULL
coactivators	NULL
include	NULL
SRC1/NCoA-1	NULL
,	NULL
GRIPL/	NULL
TIF2/NCoA2	NULL
,	NULL
ACTR/p/CIP/AIBURAC3	NULL
,	NULL
and	NULL
many	NULL
others	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
are	NULL
all	NULL
related	NULL
to	NULL
one	NULL
another	NULL
,	NULL
and	NULL
contain	NULL
a	NULL
homologous	NULL
leucine-rich	NULL
sequence	NULL
(	NULL
LXXLL	NULL
)	NULL
that	NULL
is	NULL
required	NULL
for	NULL
their	NULL
interaction	NULL
with	NULL
AF-2	NULL
domain	NULL
of	NULL
nuclear	NULL
receptors	NULL
in	NULL
a	NULL
ligand-dependent	NULL
manner	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Several	NULL
coactivators	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
nuclear	NULL
receptor	NULL
transactivation	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
.	NULL

Using	NULL
an	NULL
affinity	NULL
column	NULL
immobilizing	NULL
the	NULL
ligand	NULL
binding	NULL
domain	NULL
(	NULL
LBD	NULL
)	NULL
of	NULL
VDR	NULL
,	NULL
we	NULL
recently	NULL
isolated	NULL
a	NULL
complex	NULL
of	NULL
at	NULL
least	NULL
13	NULL
VDR	NULL
interacting	NULL
proteins	NULL
(	NULL
DRIPs	NULL
)	NULL
ranging	NULL
in	NULL
size	NULL
from	NULL
30	NULL
to	NULL
250	NULL
kDa	NULL
from	NULL
Namalwa	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
selectively	NULL
bind	NULL
as	NULL
a	NULL
complex	NULL
to	NULL
VDR	NULL
in	NULL
a	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
-dependent	NULL
manner	NULL
.	NULL

One	NULL
of	NULL
these	NULL
proteins	NULL
,	NULL
DRIP205	NULL
,	NULL
interacts	NULL
directly	NULL
with	NULL
the	NULL
LBD	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
hormone	NULL
and	NULL
appears	NULL
to	NULL
anchor	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
subunits	NULL
to	NULL
the	NULL
receptor	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
DRIP	NULL
complex	NULL
strongly	NULL
potentiated	NULL
transcription	NULL
mediated	NULL
by	NULL
VDR/RXR	NULL
in	NULL
a	NULL
cell-free	NULL
,	NULL
ligand-dependent	NULL
transcription	NULL
assay	NULL
on	NULL
chromatin-assembled	NULL
templates	NULL
.	NULL

These	NULL
observations	NULL
suggested	NULL
that	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
biological	NULL
effects	NULL
may	NULL
be	NULL
mediated	NULL
through	NULL
the	NULL
capacity	NULL
of	NULL
VDR	NULL
to	NULL
recruit	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
in	NULL
response	NULL
to	NULL
ligand	NULL
.	NULL

A	NULL
general	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
;	NULL
,	NULL
beyond	NULL
maintaining	NULL
calcium	NULL
cence-activated	NULL
cell	NULL
sorter	NULL
;	NULL
BSA	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
;	NULL
GST	NULL
,	NULL
glutathione	NULL
S-transferase	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
Alls	NULL
,	NULL
20	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Chemical	NULL
structures	NULL
of	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
and	NULL
two	NULL
20-epi	NULL
analogues	NULL
.	NULL

|	NULL
Hou	NULL
``	NULL
OH	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D3	NULL
homeostasis	NULL
is	NULL
that	NULL
of	NULL
general	NULL
inhibitor	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

The	NULL
antiproliferative	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
first	NULL
observed	NULL
in	NULL
cultured	NULL
malignant	NULL
melanoma	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

It	NULL
was	NULL
also	NULL
found	NULL
that	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
induced	NULL
the	NULL
differentiation	NULL
of	NULL
immature	NULL
mouse	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Anti-tumor	NULL
studies	NULL
of	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
have	NULL
also	NULL
been	NULL
extended	NULL
to	NULL
in	NULL
vivo	NULL
systems	NULL
,	NULL
where	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
prolonged	NULL
the	NULL
survival	NULL
time	NULL
of	NULL
mice	NULL
inoculated	NULL
with	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Since	NULL
then	NULL
,	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
has	NULL
been	NULL
found	NULL
to	NULL
inhibit	NULL
the	NULL
growth	NULL
of	NULL
a	NULL
number	NULL
of	NULL
primary	NULL
and	NULL
cultured	NULL
tumor	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
breast	NULL
,	NULL
prostate	NULL
,	NULL
colon	NULL
,	NULL
and	NULL
lymphomas	NULL
.	NULL

Although	NULL
these	NULL
findings	NULL
suggest	NULL
new	NULL
therapeutic	NULL
possibilities	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
cancer	NULL
,	NULL
deleterious	NULL
side	NULL
effects	NULL
such	NULL
as	NULL
hypercalcemia	NULL
and	NULL
soft	NULL
tissue	NULL
calcification	NULL
prevent	NULL
the	NULL
parent	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
being	NULL
used	NULL
as	NULL
a	NULL
therapeutic	NULL
agent	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
great	NULL
deal	NULL
of	NULL
effort	NULL
has	NULL
been	NULL
made	NULL
to	NULL
develop	NULL
new	NULL
vitamin	NULL
D	NULL
analogues	NULL
to	NULL
dissociate	NULL
antiproliferative	NULL
and	NULL
calcemic	NULL
activities	NULL
.	NULL

Ideal	NULL
compounds	NULL
should	NULL
have	NULL
potent	NULL
effects	NULL
in	NULL
regulating	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
at	NULL
concentrations	NULL
well	NULL
below	NULL
those	NULL
that	NULL
cause	NULL
side	NULL
effects	NULL
such	NULL
as	NULL
increased	NULL
calcium	NULL
absorption	NULL
and	NULL
bone	NULL
mineralization	NULL
.	NULL

To	NULL
date	NULL
,	NULL
several	NULL
classes	NULL
of	NULL
vitamin	NULL
D	NULL
analogues	NULL
with	NULL
high	NULL
antiproliferative	NULL
and	NULL
low	NULL
calcemic	NULL
activity	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
but	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
their	NULL
facilitated	NULL
actions	NULL
are	NULL
poorly	NULL
understood	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
20-epi	NULL
analogues	NULL
represent	NULL
a	NULL
particularly	NULL
noteworthy	NULL
group	NULL
.	NULL

They	NULL
are	NULL
characterized	NULL
by	NULL
an	NULL
inverted	NULL
stereo-chemistry	NULL
at	NULL
carbon	NULL
20	NULL
in	NULL
the	NULL
side	NULL
chain	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Their	NULL
antiproliferative	NULL
potency	NULL
is	NULL
several	NULL
orders	NULL
of	NULL
magnitude	NULL
higher	NULL
than	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
;	NULL
D	NULL
;	NULL
,	NULL
,	NULL
but	NULL
their	NULL
calcemic	NULL
activity	NULL
is	NULL
comparable	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

The	NULL
characterization	NULL
of	NULL
most	NULL
20-epi	NULL
analogues	NULL
has	NULL
revealed	NULL
that	NULL
their	NULL
affinity	NULL
for	NULL
VDR	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
vitamin	NULL
D	NULL
binding	NULL
protein	NULL
(	NULL
DBP	NULL
)	NULL
in	NULL
culture	NULL
has	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
a	NULL
20-epi	NULL
analogue	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
difference	NULL
in	NULL
cellular	NULL
uptake	NULL
of	NULL
these	NULL
ligand	NULL
mediated	NULL
by	NULL
DBP	NULL
is	NULL
unlikely	NULL
a	NULL
major	NULL
factor	NULL
for	NULL
the	NULL
augmented	NULL
activity	NULL
of	NULL
20-epi	NULL
compounds	NULL
(	NULL
18	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
conformational	NULL
effects	NULL
on	NULL
the	NULL
VDR-LBD	NULL
after	NULL
analogue	NULL
binding	NULL
dictates	NULL
their	NULL
potent	NULL
antiproliferative	NULL
effects	NULL
.	NULL

In	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
ligand	NULL
treated	NULL
cells	NULL
,	NULL
20-epi	NULL
analogue	NULL
treatment	NULL
had	NULL
significantly	NULL
stronger	NULL
effects	NULL
on	NULL
VDR/RXR-DNA	NULL
complex	NULL
formation	NULL
than	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
;	NULL
however	NULL
,	NULL
this	NULL
difference	NULL
was	NULL
limited	NULL
to	NULL
lower	NULL
concentrations	NULL
of	NULL
ligands	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
difference	NULL
between	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
20-epi	NULL
compounds	NULL
disappeared	NULL
when	NULL
using	NULL
recombinant	NULL
VDR	NULL
and	NULL
RXR	NULL
proteins	NULL
alone	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
additional	NULL
factors	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
play	NULL
critical	NULL
roles	NULL
in	NULL
20-epi	NULL
analogue-induced	NULL
transactivation	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
20-epi	NULL
analogues	NULL
may	NULL
induce	NULL
the	NULL
binding	NULL
of	NULL
key	NULL
coactivators	NULL
at	NULL
lower	NULL
concentrations	NULL
than	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
,	NULL
ultimately	NULL
leading	NULL
to	NULL
enhanced	NULL
biological	NULL
activity	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
two	NULL
20-epi	NULL
analogues	NULL
,	NULL
MC1288	NULL
and	NULL
MC1627	NULL
,	NULL
result	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
and	NULL
the	NULL
transcriptional	NULL
induction	NULL
of	NULL
16839	NULL
OH	NULL
CH	NULL
OH	NULL
MC1288	NULL
MC1627	NULL
p217*	NULL
C1	NULL
,	NULL
a	NULL
key	NULL
VDR	NULL
target	NULL
gene	NULL
involved	NULL
in	NULL
growth	NULL
inhibition	NULL
and	NULL
differentiation	NULL
(	NULL
21	NULL
)	NULL
,	NULL
at	NULL
picomolar	NULL
doses	NULL
.	NULL

Compared	NULL
with	NULL
the	NULL
interaction	NULL
of	NULL
VDR	NULL
with	NULL
RXR	NULL
or	NULL
coactivators	NULL
such	NULL
as	NULL
GRIP-1	NULL
,	NULL
this	NULL
dose-response	NULL
most	NULL
closely	NULL
correlates	NULL
to	NULL
the	NULL
ligand-dependent	NULL
recruitment	NULL
of	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
to	NULL
VDR	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
receptor	NULL
to	NULL
activate	NULL
transcription	NULL
in	NULL
vitro	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
compelling	NULL
links	NULL
between	NULL
the	NULL
efficiency	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
in	NULL
inducing	NULL
VDR/DRIP	NULL
interactions	NULL
,	NULL
VDR-RXR	NULL
transactivation	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
their	NULL
enhanced	NULL
ability	NULL
to	NULL
induce	NULL
cellular	NULL
differentiation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Ligands-1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
,	NULL
and	NULL
20-epi	NULL
analogues	NULL
(	NULL
MC1627	NULL
,	NULL
MC1288	NULL
,	NULL
and	NULL
MC1292	NULL
)	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Leo	NULL
Pharmaceutical	NULL
Products	NULL
Ltd.	NULL
(	NULL
Denmark	NULL
)	NULL
.	NULL

1,25-dihydroxy-22-oxa-vitamin	NULL
D	NULL
,	NULL
(	NULL
OCT	NULL
)	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
Chugai	NULL
Pharmaceuticals	NULL
(	NULL
Japan	NULL
)	NULL
.	NULL

Cell	NULL
Culture	NULL
and	NULL
Nuclear	NULL
Extract	NULL
Preparation-Namalwa	NULL
cells	NULL
(	NULL
ATCC	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
4-liter	NULL
spinner	NULL
flasks	NULL
and	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
5	NULL
%	NULL
calf	NULL
serum	NULL
,	NULL
and	NULL
300	NULL
ug/ml	NULL
glutamine	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

U987	NULL
cells	NULL
(	NULL
ATCC	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
300	NULL
ug/ml	NULL
glutamine	NULL
.	NULL

FACS	NULL
Analysis-Early	NULL
log-phase	NULL
growing	NULL
U9837	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
tested	NULL
ligands	NULL
ranging	NULL
from	NULL
10°	NULL
``	NULL
to	NULL
10~*	NULL
%	NULL
M	NULL
or	NULL
ethanol	NULL
for	NULL
72	NULL
h.	NULL
Approximately	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
followed	NULL
by	NULL
washing	NULL
twice	NULL
with	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

Cell	NULL
pellets	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
250	NULL
pl	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
.	NULL

2	NULL
ul	NULL
of	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
CD14	NULL
and	NULL
2	NULL
ul	NULL
of	NULL
phycoerythrin-conjugated	NULL
CD11b	NULL
(	NULL
Caltag	NULL
)	NULL
were	NULL
added	NULL
to	NULL
75	NULL
ul	NULL
of	NULL
each	NULL
sample	NULL
;	NULL
an	NULL
isotype-matched	NULL
antibody	NULL
was	NULL
incubated	NULL
with	NULL
75	NULL
pl	NULL
of	NULL
each	NULL
sample	NULL
as	NULL
a	NULL
control	NULL
for	NULL
nonspecific	NULL
binding	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
dark	NULL
on	NULL
ice	NULL
for	NULL
45	NULL
min	NULL
.	NULL

After	NULL
washing	NULL
twice	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
a	NULL
FACS	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Transient	NULL
Transfection-Approximately	NULL
10	NULL
``	NULL
U987	NULL
cells	NULL
were	NULL
col-lected	NULL
,	NULL
washed	NULL
twice	NULL
and	NULL
resuspended	NULL
in	NULL
400	NULL
ul	NULL
of	NULL
RPMI	NULL
1640	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
transiently	NULL
cotransfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
WWP-Luc	NULL
(	NULL
p21	NULL
)	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
pCMV-hVDR	NULL
,	NULL
and	NULL
8	NULL
pg	NULL
of	NULL
carrier	NULL
plasmid	NULL
(	NULL
pOTCO	NULL
)	NULL
by	NULL
electropora-tion	NULL
in	NULL
a	NULL
4-mm	NULL
cuvette	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
pooled	NULL
together	NULL
,	NULL
evenly	NULL
distributed	NULL
to	NULL
100-mm	NULL
plates	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
tested	NULL
ligands	NULL
ranging	NULL
from	NULL
10~	NULL
``	NULL
to	NULL
M	NULL
or	NULL
ethanol	NULL
for	NULL
24	NULL
h.	NULL
Treated	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
.	NULL

Cellular	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
dilution	NULL
in	NULL
cell	NULL
culture	NULL
lysis	NULL
reagent	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
measurement	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
luciferase	NULL
assay	NULL
reagent	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
a	NULL
luminometer	NULL
.	NULL

GST	NULL
Fusion	NULL
Protein	NULL
Pull-down	NULL
Assay-For	NULL
GST-VDR	NULL
LBD	NULL
and	NULL
DRIP	NULL
complex	NULL
interactions	NULL
,	NULL
40	NULL
ug	NULL
of	NULL
GST-VDR	NULL
LBD-	NULL
(	NULL
110-427	NULL
)	NULL
fusion	NULL
proteins	NULL
immobilized	NULL
on	NULL
beads	NULL
were	NULL
incubated	NULL
with	NULL
10~®	NULL
M	NULL
tested	NULL
ligands	NULL
in	NULL
GST-binding	NULL
buffer	NULL
(	NULL
20	NULL
mm	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
180	NULL
mM	NULL
KCl	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
containing	NULL
1	NULL
mg/ml	NULL
BSA	NULL
for	NULL
2	NULL
h.	NULL
GST	NULL
fusion	NULL
proteins	NULL
were	NULL
incubated	NULL
with	NULL
approximately	NULL
1	NULL
mg	NULL
of	NULL
Namalwa	NULL
nuclear	NULL
extracts	NULL
containing	NULL
200	NULL
mM	NULL
KCl	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
M	NULL
tested	NULL
ligands	NULL
or	NULL
ethanol	NULL
for	NULL
12	NULL
h.	NULL
Bound	NULL
proteins	NULL
were	NULL
washed	NULL
six	NULL
times	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
washing	NULL
buffer	NULL
(	NULL
GST-binding	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
and	NULL
eluted	NULL
by	NULL
incubation	NULL
with	NULL
GST-binding	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
and	NULL
0.15	NULL
%	NULL
Sarkosyl**	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Eluted	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
visualized	NULL
by	NULL
silver	NULL
nitrate	NULL
staining	NULL
.	NULL

For	NULL
GST-DRIP205/VDR	NULL
,	NULL
GST-RXRo/	NULL
VDR	NULL
,	NULL
or	NULL
GST-GRIP-1/VDR	NULL
interaction	NULL
assays	NULL
,	NULL
15	NULL
ug	NULL
of	NULL
fusion	NULL
proteins	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16840	NULL
A	NULL
_-	NULL
EtOH	NULL
``	NULL
ol	NULL
-	NULL
|	NULL
3354/-42	NULL
i	NULL
m	NULL
;	NULL
|	NULL
6	NULL
-	NULL
oman	NULL
1	NULL
2	NULL
203	NULL
,	NULL
4	NULL
10	NULL
10	NULL
10	NULL
10	NULL
CD14	NULL
FITC	NULL
B	NULL
_	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
pD3	NULL
10	NULL
13m	NULL
10-	NULL
!	NULL

2m	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
109m	NULL
|	NULL
2854-49	NULL
Yo	NULL
|	NULL
To	NULL
3747-42	NULL
``	NULL
o	NULL
al	NULL
1	NULL
875¥-78	NULL
]	NULL
in	NULL
``	NULL
2	NULL
w	NULL
e	NULL
``	NULL
o	NULL
=	NULL
,	NULL
|	NULL
I	NULL
fam	NULL
go	NULL
``	NULL
a	NULL
~	NULL
H	NULL
-	NULL
w	NULL
2	NULL
2	NULL
8	NULL
%	NULL
3	NULL
~	NULL
$	NULL
+	NULL
,	NULL
£4	NULL
.	NULL

a	NULL
8	NULL
F9	NULL
8	NULL
``	NULL
e	NULL
«	NULL
=-	NULL
8	NULL
``	NULL
o	NULL
:	NULL
é	NULL
``	NULL
o	NULL
!	NULL

©	NULL
o	NULL
amg	NULL
A	NULL
~~3	NULL
``	NULL
``	NULL
J	NULL
om	NULL
B	NULL
``	NULL
3p	NULL
2	NULL
*	NULL
Foam	NULL
10	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
10	NULL
%	NULL
ao	NULL
``	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
10°	NULL
10	NULL
``	NULL
10°	NULL
10°	NULL
10°	NULL
``	NULL
40°	NULL
105	NULL
102	NULL
10	NULL
%	NULL
10+	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
C	NULL
MC1627	NULL
to	NULL
J	NULL
]	NULL
|	NULL
``	NULL
el	NULL
|	NULL
»	NULL
j	NULL
o	NULL
2	NULL
}	NULL
|	NULL
f	NULL
To	NULL
*o	NULL
D	NULL
o25¥/-35	NULL
.	NULL

*s	NULL
o	NULL
H	NULL
=-	NULL
.	NULL

hall	NULL
f	NULL
a	NULL
°	NULL
a	NULL
we	NULL
2	NULL
``	NULL
o	NULL
2	NULL
o	NULL
'	NULL
a	NULL
o_	NULL
%	NULL
2	NULL
_	NULL
``	NULL
3	NULL
__	NULL
a	NULL
2	NULL
8	NULL
-	NULL
8	NULL
``	NULL
o	NULL
-	NULL
5	NULL
__	NULL
e	NULL
=	NULL
o	NULL
Ce	NULL
Fael	NULL
C	NULL
04	NULL
(	NULL
22	NULL
[	NULL
08	NULL
,	NULL
_	NULL
i	NULL
%	NULL
o	NULL
10°	NULL
405	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
10	NULL
10°	NULL
10	NULL
``	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
``	NULL
10°	NULL
10°	NULL
~40°	NULL
105	NULL
102	NULL
10	NULL
%	NULL
104	NULL
~	NULL
aat	NULL
anl	NULL
un	NULL
aat	NULL
ast	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
10	NULL
1	NULL
&	NULL
1	NULL
ZOF|T18	NULL
10	NULL
D	NULL
MC1288	NULL
``	NULL
o	NULL
rAw-14	NULL
|	NULL
000	NULL
|	NULL
[	NULL
assy-17	NULL
|	NULL
*o	NULL
|	NULL
Tesw-49	NULL
mot	NULL
h	NULL
``	NULL
o	NULL
``	NULL
3	NULL
%	NULL
3	NULL
%	NULL
a	NULL
``	NULL
oi	NULL
a	NULL
``	NULL
33	NULL
8	NULL
F9	NULL
»	NULL
--	NULL
-	NULL
-~	NULL
8	NULL
``	NULL
o	NULL
:	NULL
o	NULL
o	NULL
b	NULL
``	NULL
o	NULL
``	NULL
``	NULL
s	NULL
``	NULL
5	NULL
~	NULL
``	NULL
7	NULL
2	NULL
fom	NULL
gmu	NULL
1	NULL
CB	NULL
SC	NULL
I~	NULL
``	NULL
3°	NULL
10	NULL
19	NULL
10°	NULL
10	NULL
10	NULL
10°	NULL
10	NULL
)	NULL
10	NULL
``	NULL
10°	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10	NULL
``	NULL
10°	NULL
10°	NULL
10°	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
CD14	NULL
FITC	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Vitamin	NULL
D	NULL
analogue-induced	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
ethanol	NULL
(	NULL
4	NULL
)	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
(	NULL
B	NULL
)	NULL
,	NULL
MC1627	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
MC1288	NULL
(	NULL
D	NULL
)	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
.	NULL

After	NULL
72	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
labeled	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
CD14	NULL
and	NULL
phycoerythrin-conjugated	NULL
CD11b	NULL
.	NULL

An	NULL
isotype-matched	NULL
antibody	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
nonspecific	NULL
binding	NULL
.	NULL

Double-positive	NULL
cells	NULL
were	NULL
quantitated	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
positive	NULL
for	NULL
both	NULL
CD14	NULL
and	NULL
CD11b	NULL
,	NULL
which	NULL
is	NULL
shown	NULL
within	NULL
quadrant	NULL
boxes	NULL
.	NULL

immobilized	NULL
on	NULL
beads	NULL
were	NULL
incubated	NULL
with	NULL
GST-binding	NULL
buffer	NULL
containing	NULL
3.5	NULL
mg/ml	NULL
BSA	NULL
at	NULL
4°C	NULL
for	NULL
2	NULL
h.	NULL
GST	NULL
fusion	NULL
proteins	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
purified	NULL
recombinant	NULL
VDR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
tested	NULL
ligands	NULL
ranging	NULL
from	NULL
10~®	NULL
to	NULL
10~'*	NULL
M	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
2	NULL
h.	NULL
After	NULL
washing	NULL
three	NULL
times	NULL
,	NULL
samples	NULL
were	NULL
resolved	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophore-sis	NULL
,	NULL
followed	NULL
by	NULL
transferring	NULL
on	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
and	NULL
detected	NULL
for	NULL
VDR	NULL
binding	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

In	NULL
Vitro	NULL
Transcription	NULL
Assay-Transcription	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
with	NULL
the	NULL
following	NULL
modifications	NULL
:	NULL
20	NULL
pl	NULL
of	NULL
each	NULL
receptor	NULL
incubation	NULL
mix	NULL
including	NULL
180	NULL
ng	NULL
of	NULL
recombinant	NULL
VDR	NULL
and	NULL
RXR	NULL
plus	NULL
tested	NULL
ligands	NULL
ranging	NULL
from	NULL
10~®	NULL
to	NULL
10	NULL
~	NULL
'	NULL
``	NULL
M	NULL
or	NULL
ethanol	NULL
was	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
45	NULL
min	NULL
.	NULL

The	NULL
volume	NULL
of	NULL
receptor-ligand	NULL
mix	NULL
was	NULL
3	NULL
ul	NULL
instead	NULL
of	NULL
the	NULL
10	NULL
ul	NULL
used	NULL
in	NULL
previous	NULL
assays	NULL
(	NULL
23	NULL
)	NULL
,	NULL
and	NULL
the	NULL
volume	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
increased	NULL
to	NULL
15	NULL
ul	NULL
from	NULL
8	NULL
pl	NULL
so	NULL
that	NULL
the	NULL
final	NULL
reaction	NULL
volume	NULL
was	NULL
25	NULL
ul	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

RESULTS	NULL
Effects	NULL
of	NULL
Analogues	NULL
on	NULL
Myeloid	NULL
Cell	NULL
Differentiation-To	NULL
ex	NULL
amine	NULL
how	NULL
vitamin	NULL
D	NULL
analogues	NULL
might	NULL
influence	NULL
VDR	NULL
transcriptional	NULL
activation	NULL
,	NULL
we	NULL
first	NULL
sought	NULL
those	NULL
analogues	NULL
that	NULL
had	NULL
very	NULL
potent	NULL
effects	NULL
on	NULL
a	NULL
biological	NULL
process	NULL
which	NULL
could	NULL
then	NULL
be	NULL
correlated	NULL
to	NULL
a	NULL
transcriptional	NULL
response	NULL
.	NULL

To	NULL
do	NULL
so	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
examine	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
-induced	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
whereby	NULL
myelomonoblastic	NULL
cell	NULL
lines	NULL
,	NULL
such	NULL
as	NULL
U937	NULL
,	NULL
induce	NULL
to	NULL
differentiate	NULL
to	NULL
monocyte/macrophages	NULL
upon	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
differentiation	NULL
can	NULL
be	NULL
quantitated	NULL
by	NULL
FACS	NULL
by	NULL
assaying	NULL
the	NULL
expression	NULL
of	NULL
macrophage-specific	NULL
markers	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
such	NULL
as	NULL
CD11b	NULL
and	NULL
CD14	NULL
.	NULL

When	NULL
U937	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
10	NULL
'*	NULL
to	NULL
10~°	NULL
m	NULL
,	NULL
FACS	NULL
analyses	NULL
indicated	NULL
that	NULL
concentrations	NULL
of	NULL
10~'°	NULL
m	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
were	NULL
sufficient	NULL
to	NULL
induce	NULL
differentiation	NULL
while	NULL
concentrations	NULL
above	NULL
10~	NULL
>	NULL
m	NULL
had	NULL
no	NULL
greater	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
two	NULL
related	NULL
analogues	NULL
of	NULL
vitamin	NULL
D	NULL
belonging	NULL
to	NULL
the	NULL
20-epi	NULL
group	NULL
,	NULL
MC1288	NULL
and	NULL
MC1627	NULL
,	NULL
detectable	NULL
CD11b	NULL
and	NULL
CD14	NULL
levels	NULL
were	NULL
apparent	NULL
at	NULL
10	NULL
~	NULL
'	NULL
m	NULL
,	NULL
fully	NULL
two	NULL
orders	NULL
of	NULL
magnitude	NULL
less	NULL
than	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Maximal	NULL
CD14	NULL
and	NULL
CD11b	NULL
expression	NULL
was	NULL
detected	NULL
with	NULL
MC1627	NULL
at	NULL
10~*	NULL
'	NULL
m	NULL
;	NULL
at	NULL
this	NULL
concentration	NULL
,	NULL
no	NULL
effect	NULL
on	NULL
U937	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
20.00	NULL
€	NULL
J	NULL
-	NULL
]	NULL
3	NULL
15.00	NULL
S	NULL
E	NULL
>	NULL
10.00	NULL
5	NULL
S	NULL
J	NULL
-a	NULL
»	NULL
5.00	NULL
8	NULL
L	NULL
€	NULL
J	NULL
as	NULL
-_	NULL
0.00	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
1	NULL
1012	NULL
qo	NULL
41	NULL
40	NULL
49	NULL
40	NULL
%	NULL
qo	NULL
#	NULL
Ligand	NULL
Concentration	NULL
(	NULL
M	NULL
)	NULL
Luc	NULL
21-Luc	NULL
VDRE	NULL
P	NULL
:	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Vitamin	NULL
D	NULL
analogue-induced	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
p21	NULL
promoter	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
WWP-p21-Luc	NULL
,	NULL
a	NULL
VDR	NULL
expression	NULL
vector	NULL
(	NULL
pCMV-hVDR	NULL
)	NULL
and	NULL
carrier	NULL
DNA	NULL
by	NULL
elec-troporation	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
;	NULL
D	NULL
;	NULL
,	NULL
MC1627	NULL
,	NULL
or	NULL
MC1288	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
for	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
and	NULL
analyzed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
fold-induction	NULL
over	NULL
the	NULL
control	NULL
.	NULL

Each	NULL
value	NULL
represents	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
MC1627	NULL
,	NULL
and	NULL
MC1288	NULL
are	NULL
denoted	NULL
as	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
(	NULL
C	NULL
)	NULL
,	NULL
and	NULL
(	NULL
0	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

differentiation	NULL
was	NULL
measurable	NULL
with	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
.	NULL

We	NULL
next	NULL
asked	NULL
if	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
potent	NULL
analogues	NULL
on	NULL
myeloid	NULL
differentiation	NULL
correlated	NULL
to	NULL
VDR-mediated	NULL
activation	NULL
of	NULL
transcription	NULL
of	NULL
a	NULL
relevant	NULL
target	NULL
gene	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
identified	NULL
the	NULL
gene	NULL
among	NULL
a	NULL
set	NULL
of	NULL
several	NULL
primary	NULL
response	NULL
genes	NULL
that	NULL
are	NULL
transcriptional	NULL
targets	NULL
of	NULL
VDR	NULL
following	NULL
addition	NULL
of	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
U937	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
.	NULL

As	NULL
we	NULL
observed	NULL
before	NULL
,	NULL
treatment	NULL
of	NULL
U937	NULL
cells	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
resulted	NULL
in	NULL
a	NULL
5-to	NULL
10-fold	NULL
induction	NULL
of	NULL
p21	NULL
transcription	NULL
at	NULL
10~°	NULL
xm	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
significantly	NULL
lower	NULL
amounts	NULL
of	NULL
MC1627	NULL
and	NULL
MC1288	NULL
were	NULL
required	NULL
to	NULL
elicit	NULL
strong	NULL
p21	NULL
induction	NULL
.	NULL

A	NULL
6-fold	NULL
induction	NULL
was	NULL
apparent	NULL
at	NULL
10	NULL
~	NULL
'	NULL
m	NULL
of	NULL
MC1288	NULL
,	NULL
and	NULL
MC1627	NULL
and	NULL
peak	NULL
inductions	NULL
of	NULL
15-	NULL
to	NULL
20-fold	NULL
were	NULL
measured	NULL
at	NULL
10~'°	NULL
m	NULL
with	NULL
MC1288	NULL
and	NULL
MC1627	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

No	NULL
induction	NULL
of	NULL
p21	NULL
transcription	NULL
was	NULL
discernible	NULL
at	NULL
10	NULL
~	NULL
'°	NULL
m	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
.	NULL

The	NULL
hormone	NULL
and	NULL
analogue	NULL
effects	NULL
on	NULL
p21	NULL
transcription	NULL
correlated	NULL
remarkably	NULL
closely	NULL
to	NULL
the	NULL
differentiation	NULL
responsiveness	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
dose-response	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
on	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
mirrors	NULL
p21	NULL
transcriptional	NULL
activation	NULL
,	NULL
further	NULL
linking	NULL
differentiation	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
cell	NULL
cycle	NULL
inhibitor	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
20-Epi	NULL
Analogues	NULL
on	NULL
VDR-Cofactor	NULL
Interactions-Because	NULL
of	NULL
the	NULL
astonishingly	NULL
potent	NULL
effects	NULL
the	NULL
20-epi	NULL
compounds	NULL
had	NULL
on	NULL
p21	NULL
induction	NULL
and	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
their	NULL
activity	NULL
could	NULL
be	NULL
correlated	NULL
with	NULL
an	NULL
enhancement	NULL
of	NULL
known	NULL
VDR-protein	NULL
interactions	NULL
that	NULL
are	NULL
functionally	NULL
important	NULL
.	NULL

Such	NULL
interactions	NULL
would	NULL
in-clude	NULL
,	NULL
for	NULL
example	NULL
,	NULL
VDR-coactivator	NULL
binding	NULL
or	NULL
ligand-stimu-lated	NULL
dimerization	NULL
.	NULL

An	NULL
obligatory	NULL
cofactor	NULL
for	NULL
VDR	NULL
transactivation	NULL
is	NULL
its	NULL
heterodimeric	NULL
partner	NULL
,	NULL
RXR	NULL
.	NULL

We	NULL
previously	NULL
reported	NULL
that	NULL
three	NULL
analogues	NULL
containing	NULL
16-ene-23-yne-D	NULL
;	NULL
substitutions	NULL
conferred	NULL
distinct	NULL
rate	NULL
and	NULL
equilibrium	NULL
constants	NULL
for	NULL
VDR-RXR	NULL
heterodimerization	NULL
and	NULL
specific	NULL
DNA	NULL
binding	NULL
to	NULL
a	NULL
VDRE	NULL
relative	NULL
to	NULL
the	NULL
natural	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
ligand	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
used	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
fusion	NULL
to	NULL
RXR	NULL
16841	NULL
A	NULL
est-rxr+vor	NULL
Western	NULL
:	NULL
anti-VDR	NULL
Ab	NULL
~	NULL
10	NULL
Bao	NULL
m	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D3	NULL
wonen	NULL
wn	NULL
week	NULL
GBP	NULL
MC1627	NULL
Su..	NULL
aap	NULL
amer	NULL
MC1288	NULL
<	NULL
-	NULL
sue	NULL
que	NULL
Percentage	NULL
of	NULL
Maximal	NULL
Induction	NULL
0	NULL
1-13	NULL
“	NULL
3-12	NULL
1g	NULL
!	NULL

‘	NULL
O-IC	NULL
'	NULL
10-9	NULL
Ligand	NULL
Concentration	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Vitamin	NULL
D	NULL
analogue-induced	NULL
interaction	NULL
between	NULL
GST-RXR	NULL
and	NULL
VDR	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
,	NULL
GST-RXR	NULL
was	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
immobilized	NULL
on	NULL
glutathione-Sepharose	NULL
beads	NULL
.	NULL

After	NULL
preincubation	NULL
with	NULL
GST-binding	NULL
buffer	NULL
containing	NULL
BSA	NULL
for	NULL
2	NULL
h	NULL
,	NULL
the	NULL
beads	NULL
were	NULL
incubated	NULL
with	NULL
recombinant	NULL
VDR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
;	NULL
D	NULL
;	NULL
,	NULL
MC1627	NULL
,	NULL
or	NULL
MC1288	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
or	NULL
ethanol	NULL
for	NULL
2	NULL
h	NULL
followed	NULL
by	NULL
extensive	NULL
washing	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
with	NULL
rat	NULL
monoclonal	NULL
anti-VDR	NULL
antibody	NULL
was	NULL
performed	NULL
to	NULL
detect	NULL
VDR	NULL
binding	NULL
.	NULL

Autoradiographs	NULL
were	NULL
digitally	NULL
scanned	NULL
and	NULL
quantitated	NULL
by	NULL
MacBas	NULL
Version	NULL
2.5	NULL
pro-gram	NULL
;	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
.	NULL

1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
,	NULL
MC1627	NULL
,	NULL
and	NULL
MC1288	NULL
are	NULL
denoted	NULL
as	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
(	NULL
)	NULL
,	NULL
and	NULL
(	NULL
0	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

to	NULL
perform	NULL
in	NULL
vitro	NULL
pull-down	NULL
assays	NULL
with	NULL
purified	NULL
VDR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
the	NULL
two	NULL
20-epi	NULL
analogues	NULL
.	NULL

When	NULL
compared	NULL
with	NULL
the	NULL
natural	NULL
ligand	NULL
,	NULL
MC1627	NULL
was	NULL
able	NULL
to	NULL
stimulate	NULL
VDR/RXR	NULL
heterodimerization	NULL
at	NULL
a	NULL
lower	NULL
dose	NULL
(	NULL
10~	NULL
``	NULL
m	NULL
)	NULL
,	NULL
whereas	NULL
MC1288	NULL
did	NULL
not	NULL
differ	NULL
significantly	NULL
from	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

At	NULL
10~*	NULL
m	NULL
,	NULL
a	NULL
greater	NULL
stimulation	NULL
of	NULL
heterodimerization	NULL
was	NULL
observed	NULL
with	NULL
both	NULL
analogues	NULL
than	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
a	NULL
contribution	NULL
of	NULL
the	NULL
20-epi	NULL
compounds	NULL
on	NULL
VDR-RXR	NULL
heterodimerization	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
analogues	NULL
on	NULL
dimerization	NULL
per	NULL
se	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
mirror	NULL
the	NULL
same	NULL
dose-response	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
differentiation	NULL
and	NULL
p21	NULL
transactivation	NULL
assays	NULL
.	NULL

Recruitment	NULL
of	NULL
transcriptional	NULL
coactivators	NULL
by	NULL
VDR	NULL
is	NULL
also	NULL
regulated	NULL
by	NULL
VDR	NULL
ligands	NULL
.	NULL

Such	NULL
coactivators	NULL
include	NULL
SRCU/	NULL
NCoA-1	NULL
,	NULL
_	NULL
GRIPI/TIF2Z/NCoA2	NULL
,	NULL
_	NULL
ACTR/p/CIP/AIBIURAC3	NULL
,	NULL
P/CAF	NULL
,	NULL
and	NULL
CBP/p300	NULL
.	NULL

Several	NULL
of	NULL
these	NULL
coactivators	NULL
(	NULL
i.e	NULL
.	NULL

the	NULL
p160	NULL
family	NULL
)	NULL
are	NULL
structurally	NULL
related	NULL
and	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
possess	NULL
histone	NULL
acetyl	NULL
transferase	NULL
activity	NULL
.	NULL

To	NULL
test	NULL
the	NULL
effect	NULL
the	NULL
20-epi	NULL
analogues	NULL
had	NULL
on	NULL
the	NULL
interaction	NULL
between	NULL
VDR	NULL
and	NULL
members	NULL
of	NULL
the	NULL
p160	NULL
family	NULL
,	NULL
we	NULL
assessed	NULL
GRIP-1/VDR	NULL
interactions	NULL
as	NULL
an	NULL
example	NULL
using	NULL
a	NULL
GST	NULL
pull-down	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
MC1627	NULL
but	NULL
not	NULL
MC1288	NULL
was	NULL
more	NULL
effective	NULL
than	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
at	NULL
lower	NULL
concentrations	NULL
in	NULL
inducing	NULL
the	NULL
GRIP/VDR	NULL
interaction	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
concentrations	NULL
required	NULL
for	NULL
inducing	NULL
50	NULL
%	NULL
of	NULL
maximal	NULL
VDR/GRIP-1	NULL
interaction	NULL
were	NULL
5.9	NULL
X	NULL
107	NULL
``	NULL
,	NULL
4.7	NULL
x	NULL
10~	NULL
``	NULL
``	NULL
,	NULL
and	NULL
4	NULL
x	NULL
10~*	NULL
``	NULL
'	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
MC1288	NULL
,	NULL
and	NULL
-	NULL
MC1627	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
difference	NULL
between	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
and	NULL
MC1627	NULL
is	NULL
approximately	NULL
1	NULL
log	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
and	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
the	NULL
2	NULL
log	NULL
difference	NULL
observed	NULL
using	NULL
U937	NULL
differentiation	NULL
or	NULL
p21	NULL
transactivation	NULL
as	NULL
a	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16842	NULL
GST-GRIP-1	NULL
+	NULL
VDR	NULL
Western	NULL
:	NULL
anti-VDR	NULL
Ab	NULL
~	NULL
ad	NULL
aot	NULL
aot	NULL
``	NULL
aot	NULL
aot	NULL
om	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
--	NULL
selec	NULL
cmm	NULL
MC1627	NULL
--	NULL
camp	NULL
camp	NULL
MC1288	NULL
--	NULL
<	NULL
>	NULL
«	NULL
wam	NULL
Percentage	NULL
of	NULL
Maximal	NULL
Induction	NULL
ra	NULL
2	NULL
ae	NULL
540°	NULL
49°	NULL
``	NULL
an	NULL
``	NULL
Ligand	NULL
Concentration	NULL
(	NULL
M	NULL
)	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Vitamin	NULL
D	NULL
analogue-induced	NULL
interaction	NULL
between	NULL
GST-GRIP-1	NULL
and	NULL
VDR	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
,	NULL
GST-GRIP-1	NULL
was	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
and	NULL
immobilized	NULL
on	NULL
glutathione-Sepharose	NULL
beads	NULL
.	NULL

Pull-downs	NULL
,	NULL
detection	NULL
,	NULL
and	NULL
quantitation	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

B	NULL
,	NULL
quantitation	NULL
corresponding	NULL
to	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
MC1627	NULL
,	NULL
and	NULL
MC1288	NULL
are	NULL
denoted	NULL
as	NULL
(	NULL
L	NULL
]	NULL
)	NULL
,	NULL
(	NULL
)	NULL
,	NULL
and	NULL
(	NULL
0	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

readout	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
not	NULL
likely	NULL
that	NULL
the	NULL
increased	NULL
effect	NULL
these	NULL
analogues	NULL
have	NULL
on	NULL
VDR	NULL
activity	NULL
is	NULL
because	NULL
of	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
the	NULL
GRIP-1/VDR	NULL
induction	NULL
.	NULL

Effects	NULL
of	NULL
Analogues	NULL
on	NULL
VDR-DRIP	NULL
Interactions-Because	NULL
the	NULL
20-epi	NULL
analogues	NULL
did	NULL
modulate	NULL
GRIP-1/VDR	NULL
binding	NULL
some-what	NULL
,	NULL
we	NULL
considered	NULL
whether	NULL
they	NULL
might	NULL
affect	NULL
binding	NULL
between	NULL
VDR	NULL
and	NULL
other	NULL
coactivators	NULL
.	NULL

The	NULL
DRIPs	NULL
comprise	NULL
a	NULL
multiprotein	NULL
coactivator	NULL
complex	NULL
of	NULL
at	NULL
least	NULL
thirteen	NULL
subunits	NULL
that	NULL
we	NULL
recently	NULL
discovered	NULL
and	NULL
have	NULL
been	NULL
characterizing	NULL
that	NULL
bind	NULL
to	NULL
VDR	NULL
and	NULL
other	NULL
nuclear	NULL
receptors	NULL
in	NULL
a	NULL
strictly	NULL
ligand-dependent	NULL
manner	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

The	NULL
DRIP	NULL
complex	NULL
lacks	NULL
histone	NULL
acetyl	NULL
transferase	NULL
activity	NULL
,	NULL
and	NULL
its	NULL
individual	NULL
subunits	NULL
do	NULL
not	NULL
share	NULL
any	NULL
homology	NULL
to	NULL
other	NULL
characterized	NULL
coactivators	NULL
(	NULL
12	NULL
)	NULL
.	NULL

A	NULL
single	NULL
subunit	NULL
,	NULL
DRIP205	NULL
,	NULL
directly	NULL
associates	NULL
with	NULL
VDR	NULL
via	NULL
its	NULL
ligand-binding	NULL
domain	NULL
.	NULL

This	NULL
association	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
AF-2	NULL
subdomain	NULL
of	NULL
the	NULL
receptor	NULL
and	NULL
one	NULL
of	NULL
two	NULL
LXXLL	NULL
(	NULL
NR	NULL
)	NULL
motifs	NULL
in	NULL
the	NULL
central	NULL
portion	NULL
of	NULL
DRIP205	NULL
(	NULL
residues	NULL
630-635	NULL
)	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
the	NULL
20-epi	NULL
analogues	NULL
affected	NULL
the	NULL
DRIP205/	NULL
VDR	NULL
interaction	NULL
,	NULL
we	NULL
employed	NULL
a	NULL
GST	NULL
fusion	NULL
protein	NULL
containing	NULL
the	NULL
nuclear	NULL
receptor	NULL
interaction	NULL
domain	NULL
of	NULL
DRIP205	NULL
to	NULL
pull-down	NULL
purified	NULL
VDR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
or	NULL
the	NULL
20-epi	NULL
compounds	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
10	NULL
'*	NULL
to	NULL
10	NULL
®	NULL
M.	NULL
The	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
illustrate	NULL
that	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
induced	NULL
the	NULL
association	NULL
of	NULL
VDR	NULL
and	NULL
DRIP205	NULL
in	NULL
a	NULL
dose-depend-ent	NULL
manner	NULL
,	NULL
beginning	NULL
at	NULL
10	NULL
~	NULL
'	NULL
m.	NULL
MC1627	NULL
and	NULL
MC1288	NULL
exhibited	NULL
significantly	NULL
more	NULL
potent	NULL
effects	NULL
on	NULL
VDR/DRIP205	NULL
interactions	NULL
than	NULL
the	NULL
natural	NULL
ligand	NULL
.	NULL

The	NULL
minimum	NULL
concentration	NULL
required	NULL
for	NULL
inducing	NULL
the	NULL
VDR/DRIP205	NULL
association	NULL
was	NULL
10	NULL
~	NULL
'	NULL
m	NULL
,	NULL
at	NULL
least	NULL
100	NULL
times	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A	NULL
and	NULL
B	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
two	NULL
additional	NULL
vitamin	NULL
D	NULL
compounds	NULL
for	NULL
their	NULL
effects	NULL
on	NULL
VDR/DRIP205	NULL
interaction	NULL
.	NULL

MC1292	NULL
,	NULL
which	NULL
,	NULL
relative	NULL
to	NULL
other	NULL
20-epi	NULL
compounds	NULL
,	NULL
induces	NULL
a	NULL
distinct	NULL
conformation	NULL
in	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
A	NULL
GST-DRIP206	NULL
+	NULL
VDR	NULL
Western	NULL
:	NULL
anti-VDR	NULL
Ab	NULL
mao	NULL
Rad	NULL
ao	NULL
``	NULL
108	NULL
108	NULL
107108	NULL
m	NULL
_-	NULL
\_	NULL
.	NULL

ce	NULL
eme	NULL
eme	NULL
|	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
qD3	NULL
~-	NULL
«	NULL
o	NULL
gus	NULL
as	NULL
cus	NULL
«	NULL
#	NULL
MC1288	NULL
MC1292	NULL
oct	NULL
1.25	NULL
0.25	NULL
Percentage	NULL
of	NULL
Maximal	NULL
Induction	NULL
e	NULL
ia	NULL
d	NULL
as	NULL
``	NULL
aq	NULL
18	NULL
``	NULL
19	NULL
``	NULL
as	NULL
``	NULL
an	NULL
ao	NULL
Ligand	NULL
Concentration	NULL
|	NULL
(	NULL
M	NULL
)	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Vitamin	NULL
D	NULL
analogue-induced	NULL
interaction	NULL
between	NULL
GST-DRIP	NULL
205	NULL
and	NULL
VDR	NULL
proteins	NULL
.	NULL

A	NULL
,	NULL
GST-DRIP	NULL
205	NULL
(	NULL
residues	NULL
488	NULL
to	NULL
739	NULL
)	NULL
was	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
and	NULL
immobilized	NULL
on	NULL
glutathione-Sepharose	NULL
beads	NULL
.	NULL

Pull-downs	NULL
,	NULL
detection	NULL
,	NULL
and	NULL
quantitation	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

B	NULL
,	NULL
quantitation	NULL
corresponding	NULL
to	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
,	NULL
MC1627	NULL
,	NULL
and	NULL
MC1288	NULL
are	NULL
denoted	NULL
as	NULL
(	NULL
0	NULL
)	NULL
,	NULL
(	NULL
©	NULL
)	NULL
,	NULL
(	NULL
0	NULL
)	NULL
,	NULL
OCT	NULL
(	NULL
EH	NULL
)	NULL
,	NULL
and	NULL
MC1292	NULL
(	NULL
A	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

TaBLE	NULL
I	NULL
Effective	NULL
dose	NULL
required	NULL
for	NULL
50	NULL
%	NULL
maximal	NULL
VDR/coactivator	NULL
interaction	NULL
(	NULL
ED	NULL
;	NULL
)	NULL
Analogue	NULL
DRIP	NULL
205	NULL
CRIP	NULL
M	NULL
1,25	NULL
(	NULL
0OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
7.0	NULL
x	NULL
10°	NULL
5.9	NULL
x	NULL
10-	NULL
``	NULL
°	NULL
MC1627	NULL
3.0	NULL
x	NULL
10	NULL
%	NULL
4.0	NULL
x	NULL
10-*	NULL
MC1288	NULL
7.0	NULL
x	NULL
10-2	NULL
4.7	NULL
%	NULL
100°	NULL
MC1292	NULL
2.2	NULL
x	NULL
10°	NULL
OCT	NULL
8.0	NULL
x	NULL
10-°	NULL
the	NULL
VDR-LBD	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
protease	NULL
digestion	NULL
patterns	NULL
,	NULL
``	NULL
and	NULL
confers	NULL
a	NULL
relatively	NULL
low	NULL
antiproliferative	NULL
activity	NULL
(	NULL
only	NULL
4-fold	NULL
higher	NULL
than	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
(	NULL
17	NULL
)	NULL
,	NULL
here	NULL
showed	NULL
a	NULL
similar	NULL
VDR/DRIP	NULL
binding	NULL
pattern	NULL
as	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
.	NULL

Similarly	NULL
,	NULL
a	NULL
chemically	NULL
distinct	NULL
vitamin	NULL
D	NULL
;	NULL
analogue	NULL
,	NULL
OCT	NULL
,	NULL
conferred	NULL
weaker	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
VDR-DRIP205	NULL
interaction	NULL
than	NULL
the	NULL
20-epi	NULL
compounds	NULL
and	NULL
even	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A	NULL
and	NULL
B	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
may	NULL
occur	NULL
selectively	NULL
through	NULL
VDR/DRIP	NULL
recruitment	NULL
.	NULL

Taking	NULL
together	NULL
all	NULL
the	NULL
data	NULL
from	NULL
Figs	NULL
.	NULL

4-6	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
most	NULL
potent	NULL
effects	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
on	NULL
VDR-cofactor	NULL
interactions	NULL
occur	NULL
between	NULL
the	NULL
receptor	NULL
and	NULL
DRIP205	NULL
.	NULL

This	NULL
observation	NULL
suggests	NULL
that	NULL
the	NULL
DRIP	NULL
complex	NULL
is	NULL
the	NULL
preferred	NULL
VDR	NULL
coactivator	NULL
complex	NULL
,	NULL
at	NULL
least	NULL
in	NULL
response	NULL
to	NULL
the	NULL
20-epi	NULL
analogues	NULL
.	NULL

Influence	NULL
of	NULL
20-Epi	NULL
Analogues	NULL
on	NULL
VDR	NULL
Transactivation	NULL
in	NULL
Vitro-The	NULL
VDR-DRIP205	NULL
results	NULL
suggested	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
vitamin	NULL
D	NULL
analogues	NULL
to	NULL
induce	NULL
VDR-DRIP	NULL
binding	NULL
might	NULL
cor-	NULL
2	NULL
L.	NULL
Binderup	NULL
,	NULL
personal	NULL
communication	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D	NULL
wy	NULL
|	NULL
s	NULL
ox	NULL
51163233	NULL
£00	NULL
.	NULL

%	NULL
0g	NULL
0	NULL
.	NULL

_	NULL
DRIP	NULL
rn	NULL
MC1627	NULL
0	NULL
%	NULL
%	NULL
m2	NULL
;	NULL
==	NULL
250/240	NULL
ass	NULL
pean	NULL
2506	NULL
220	NULL
Teo	NULL
ou	NULL
i	NULL
gg=t=1soiso	NULL
120	NULL
'	NULL
100	NULL
fewest	NULL
10097	NULL
c	NULL
m	NULL
ma-	NULL
``	NULL
puss	NULL
4-70	NULL
2	NULL
3	NULL
4	NULL
|	NULL
1	NULL
B	NULL
in	NULL
vitro	NULL
transcription	NULL
-	NULL
-	NULL
4002	NULL
10	NULL
10°	NULL
10°	NULL
M	NULL
[	NULL
ligand	NULL
]	NULL
wo	NULL
#	NULL
»	NULL
..	NULL
J	NULL
.|	NULL
is	NULL
ap	NULL
g	NULL
!	NULL
'	NULL

mci1627	NULL
16843	NULL
``	NULL
to-	NULL
Fold	NULL
-	NULL
Transcription	NULL
10	NULL
Raa	NULL
ae	NULL
109	NULL
108	NULL
Ligand	NULL
-	NULL
Concentration	NULL
-	NULL
(	NULL
M	NULL
)	NULL
FiG	NULL
.	NULL

7	NULL
.	NULL

A	NULL
,	NULL
vitamin	NULL
D	NULL
analogue-dependent	NULL
interaction	NULL
between	NULL
the	NULL
VDR	NULL
LBD	NULL
and	NULL
the	NULL
multisubunit	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
from	NULL
Namalwa	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

Immobilized	NULL
GST-VDR	NULL
LBD	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
Namalwa	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ethanol	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
or	NULL
MC1627	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
MC1288	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
all	NULL
at	NULL
10~®	NULL
M.	NULL
Bound	NULL
proteins	NULL
were	NULL
eluted	NULL
by	NULL
incubation	NULL
with	NULL
N-lauroylsarcosine	NULL
.	NULL

Eluted	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
7.5	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
visualized	NULL
by	NULL
silver	NULL
nitrate	NULL
staining	NULL
.	NULL

B	NULL
,	NULL
vitamin	NULL
D	NULL
analogue-induced	NULL
transcriptional	NULL
activity	NULL
in	NULL
a	NULL
cell-free	NULL
transcription	NULL
assay	NULL
.	NULL

50	NULL
ng	NULL
of	NULL
VDR-RXR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ethanol	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
tested	NULL
ligands	NULL
at	NULL
indicated	NULL
concentrations	NULL
were	NULL
used	NULL
.	NULL

A	NULL
VDRE-linked	NULL
E1B	NULL
promoter	NULL
G-less	NULL
cassette	NULL
template	NULL
and	NULL
a	NULL
reference	NULL
template	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
included	NULL
in	NULL
each	NULL
reaction	NULL
.	NULL

Transcription	NULL
was	NULL
initiated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
nucleoside	NULL
triphosphates	NULL
and	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
45	NULL
min	NULL
.	NULL

Radiolabeled	NULL
transcripts	NULL
were	NULL
recovered	NULL
and	NULL
separated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Data	NULL
was	NULL
quantitated	NULL
with	NULL
MacBas	NULL
Version	NULL
2.5	NULL
program	NULL
.	NULL

C	NULL
,	NULL
quantitation	NULL
of	NULL
data	NULL
shown	NULL
in	NULL
panel	NULL
!	NULL

B	NULL
.	NULL

The	NULL
results	NULL
are	NULL
normalized	NULL
to	NULL
a	NULL
reference	NULL
template	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold-induction	NULL
over	NULL
the	NULL
(	NULL
-	NULL
)	NULL
ligand	NULL
control	NULL
set	NULL
at	NULL
a	NULL
value	NULL
of	NULL
1.0	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
,	NULL
,	NULL
MC1627	NULL
,	NULL
and	NULL
MC1288	NULL
are	NULL
denoted	NULL
as	NULL
(	NULL
L	NULL
]	NULL
)	NULL
,	NULL
(	NULL
©	NULL
)	NULL
,	NULL
and	NULL
(	NULL
0	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

relate	NULL
with	NULL
their	NULL
effects	NULL
on	NULL
VDR-mediated	NULL
transactivation	NULL
,	NULL
since	NULL
we	NULL
have	NULL
previously	NULL
found	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
to	NULL
a	NULL
purified	NULL
transcription	NULL
system	NULL
strongly	NULL
potentiated	NULL
VDR-RXR	NULL
transactivation	NULL
in	NULL
response	NULL
to	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
20-epi	NULL
compounds	NULL
conferred	NULL
the	NULL
most	NULL
potent	NULL
effect	NULL
on	NULL
VDR-DRIP205	NULL
binding	NULL
,	NULL
and	NULL
DRIP205	NULL
anchors	NULL
the	NULL
entire	NULL
complex	NULL
to	NULL
VDR	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
focus	NULL
our	NULL
efforts	NULL
on	NULL
this	NULL
class	NULL
of	NULL
vitamin	NULL
D	NULL
analogues	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
MC1288	NULL
and	NULL
MC1627	NULL
were	NULL
able	NULL
to	NULL
stimulate	NULL
a	NULL
stronger	NULL
degree	NULL
of	NULL
recruitment	NULL
of	NULL
several	NULL
subunits	NULL
of	NULL
the	NULL
DRIP	NULL
coactivator	NULL
complex	NULL
than	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
10~®	NULL
x	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
binding	NULL
to	NULL
VDR	NULL
of	NULL
DRIP250	NULL
,	NULL
240	NULL
,	NULL
205	NULL
,	NULL
100	NULL
,	NULL
and	NULL
97	NULL
were	NULL
enhanced	NULL
by	NULL
the	NULL
20-epi	NULL
compounds	NULL
relative	NULL
to	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

To	NULL
directly	NULL
link	NULL
VDR/DRIP	NULL
binding	NULL
in	NULL
response	NULL
to	NULL
analogue	NULL
dose	NULL
to	NULL
transcriptional	NULL
activity	NULL
,	NULL
we	NULL
repeated	NULL
the	NULL
20-epi	NULL
analogue	NULL
titration	NULL
using	NULL
a	NULL
cell-free	NULL
,	NULL
VDR-RXR-responsive	NULL
transcription	NULL
assay	NULL
.	NULL

This	NULL
allowed	NULL
us	NULL
to	NULL
monitor	NULL
VDR	NULL
transcriptional	NULL
enhancement	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
analogue	NULL
potency	NULL
without	NULL
the	NULL
confounding	NULL
effects	NULL
that	NULL
cellular	NULL
uptake	NULL
or	NULL
metabolism	NULL
of	NULL
the	NULL
compounds	NULL
might	NULL
have	NULL
on	NULL
the	NULL
biological	NULL
readout	NULL
.	NULL

With	NULL
the	NULL
natural	NULL
ligand	NULL
,	NULL
activation	NULL
by	NULL
VDR-RXR	NULL
above	NULL
basal	NULL
levels	NULL
was	NULL
weakly	NULL
detectable	NULL
at	NULL
10~	NULL
>	NULL
m	NULL
and	NULL
reproducibly	NULL
strong	NULL
at	NULL
10~°	NULL
m	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

As	NULL
was	NULL
the	NULL
case	NULL
with	NULL
both	NULL
the	NULL
VDR/DRIP205	NULL
and	NULL
VDR/DRIP	NULL
complex	NULL
interactions	NULL
,	NULL
the	NULL
two	NULL
20-epi	NULL
compounds	NULL
showed	NULL
a	NULL
stronger	NULL
transactivation	NULL
by	NULL
VDR-RXR	NULL
in	NULL
vitro	NULL
at	NULL
both	NULL
of	NULL
these	NULL
concentrations	NULL
;	NULL
moreover	NULL
,	NULL
some	NULL
analogue-stimulated	NULL
transcription	NULL
could	NULL
be	NULL
observed	NULL
as	NULL
low	NULL
as	NULL
10~'°	NULL
x	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
a	NULL
strong	NULL
correlation	NULL
between	NULL
the	NULL
proclivity	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
to	NULL
recruit	NULL
the	NULL
DRIP	NULL
complex	NULL
and	NULL
their	NULL
ability	NULL
to	NULL
stimulate	NULL
VDR-RXR	NULL
transactivation	NULL
in	NULL
vitro	NULL
at	NULL
lower	NULL
concentrations	NULL
than	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

DISCUSSION	NULL
The	NULL
promising	NULL
therapeutic	NULL
potential	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
has	NULL
stimulated	NULL
interest	NULL
in	NULL
developing	NULL
similar	NULL
vitamin	NULL
D	NULL
compounds	NULL
for	NULL
a	NULL
variety	NULL
of	NULL
clinical	NULL
applications	NULL
.	NULL

Although	NULL
several	NULL
classes	NULL
of	NULL
analogues	NULL
with	NULL
high	NULL
antiproliferative	NULL
but	NULL
low	NULL
calcemic	NULL
activities	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
these	NULL
analogues	NULL
possess	NULL
potent	NULL
effects	NULL
in	NULL
regulating	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
are	NULL
poorly	NULL
understood	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
whether	NULL
these	NULL
compounds	NULL
work	NULL
indirectly	NULL
via	NULL
pharmacokinetic	NULL
phenomena	NULL
or	NULL
through	NULL
direct	NULL
conformational	NULL
changes	NULL
on	NULL
VDR	NULL
is	NULL
still	NULL
a	NULL
matter	NULL
for	NULL
debate	NULL
.	NULL

It	NULL
is	NULL
certainly	NULL
reasonable	NULL
to	NULL
assume	NULL
that	NULL
either	NULL
mechanism	NULL
is	NULL
not	NULL
mutually	NULL
exclusive	NULL
,	NULL
in	NULL
that	NULL
different	NULL
classes	NULL
of	NULL
compounds	NULL
act	NULL
through	NULL
either	NULL
route	NULL
.	NULL

20-epi	NULL
analogues	NULL
were	NULL
identified	NULL
initially	NULL
as	NULL
potent	NULL
inhibitors	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

Because	NULL
previous	NULL
characterization	NULL
of	NULL
this	NULL
particular	NULL
group	NULL
has	NULL
suggested	NULL
that	NULL
their	NULL
intrinsic	NULL
binding	NULL
affinities	NULL
for	NULL
VDR	NULL
and	NULL
DBP	NULL
do	NULL
not	NULL
differ	NULL
from	NULL
those	NULL
of	NULL
the	NULL
natural	NULL
ligand	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
20-epi	NULL
compounds	NULL
represent	NULL
a	NULL
class	NULL
of	NULL
compounds	NULL
that	NULL
might	NULL
instead	NULL
act	NULL
by	NULL
affecting	NULL
VDR	NULL
structure	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
would	NULL
somehow	NULL
lead	NULL
to	NULL
enhanced	NULL
VDR	NULL
function	NULL
and	NULL
biological	NULL
activity	NULL
.	NULL

Previous	NULL
studies	NULL
using	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
ligand-treated	NULL
cells	NULL
indicated	NULL
that	NULL
20-epi	NULL
analogues	NULL
at	NULL
low	NULL
concentrations	NULL
have	NULL
much	NULL
stronger	NULL
effects	NULL
on	NULL
VDR/RXR-DNA	NULL
complex	NULL
formation	NULL
than	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
(	NULL
19	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
results	NULL
could	NULL
not	NULL
be	NULL
duplicated	NULL
in	NULL
a	NULL
cell-free	NULL
system	NULL
with	NULL
recombinant	NULL
VDR	NULL
and	NULL
RXR	NULL
alone	NULL
(	NULL
20	NULL
)	NULL
.	NULL

We	NULL
performed	NULL
pull-down	NULL
assays	NULL
with	NULL
purified	NULL
RXR	NULL
and	NULL
VDR	NULL
to	NULL
examine	NULL
the	NULL
ligand	NULL
effect	NULL
on	NULL
VDR/RXR	NULL
dimerization	NULL
and	NULL
found	NULL
little	NULL
or	NULL
no	NULL
difference	NULL
between	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
and	NULL
20-epi	NULL
analogues	NULL
at	NULL
low	NULL
concentrations	NULL
.	NULL

20-epi	NULL
analogues	NULL
are	NULL
therefore	NULL
unlikely	NULL
to	NULL
affect	NULL
VDR-mediated	NULL
transactivation	NULL
through	NULL
enhanced	NULL
VDR/	NULL
RXR	NULL
dimerization	NULL
;	NULL
instead	NULL
,	NULL
these	NULL
analogues	NULL
appear	NULL
to	NULL
increase	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
16844	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
VDR	NULL
by	NULL
inducing	NULL
receptor	NULL
interaction	NULL
with	NULL
coactivators	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
that	NULL
are	NULL
important	NULL
for	NULL
VDR-mediated	NULL
transactivation	NULL
,	NULL
such	NULL
as	NULL
p160	NULL
family	NULL
members	NULL
,	NULL
like	NULL
GRIP-1	NULL
,	NULL
or	NULL
,	NULL
more	NULL
potently	NULL
,	NULL
DRIP205	NULL
,	NULL
the	NULL
subunit	NULL
bridging	NULL
the	NULL
interaction	NULL
of	NULL
VDR	NULL
with	NULL
the	NULL
multi-protein	NULL
DRIP	NULL
complex	NULL
.	NULL

The	NULL
dose-response	NULL
patterns	NULL
of	NULL
DRIP	NULL
recruitment	NULL
by	NULL
VDR	NULL
in	NULL
response	NULL
to	NULL
MC1627	NULL
and	NULL
MC1288	NULL
were	NULL
remarkably	NULL
similar	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
U937	NULL
cell	NULL
differentiation	NULL
and	NULL
p21	NULL
transactivation	NULL
at	NULL
the	NULL
same	NULL
low	NULL
concentrations	NULL
of	NULL
these	NULL
compounds	NULL
.	NULL

That	NULL
these	NULL
cellular	NULL
responses	NULL
to	NULL
the	NULL
analogues	NULL
are	NULL
occurring	NULL
through	NULL
the	NULL
ability	NULL
of	NULL
VDR	NULL
to	NULL
regulate	NULL
transcription	NULL
is	NULL
closely	NULL
correlated	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
20-epi	NULL
analogues	NULL
to	NULL
induce	NULL
VDR-RXR-dependent	NULL
transactivation	NULL
in	NULL
a	NULL
cell-free	NULL
,	NULL
in	NULL
vitro	NULL
transcription	NULL
system	NULL
at	NULL
concentrations	NULL
(	NULL
.e	NULL
.	NULL

10	NULL
~*	NULL
m	NULL
)	NULL
at	NULL
least	NULL
100-fold	NULL
lower	NULL
than	NULL
the	NULL
minimum	NULL
concentration	NULL
required	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

To	NULL
our	NULL
knowl-edge	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
direct	NULL
demonstration	NULL
that	NULL
vitamin	NULL
D	NULL
analogues	NULL
can	NULL
act	NULL
directly	NULL
at	NULL
the	NULL
level	NULL
of	NULL
gene	NULL
transcription	NULL
and	NULL
provides	NULL
the	NULL
best	NULL
evidence	NULL
to	NULL
date	NULL
that	NULL
some	NULL
classes	NULL
of	NULL
analogues	NULL
can	NULL
influence	NULL
biological	NULL
readouts	NULL
directly	NULL
through	NULL
VDR-dependent	NULL
transactivation	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
our	NULL
results	NULL
,	NULL
the	NULL
reported	NULL
IC	NULL
;	NULL
,	NULL
for	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
by	NULL
the	NULL
20-epi	NULL
analogues	NULL
correlates	NULL
with	NULL
their	NULL
ED	NULL
;	NULL
,	NULL
for	NULL
VDR/DRIP	NULL
205	NULL
interaction	NULL
.	NULL

For	NULL
example	NULL
,	NULL
IC	NULL
,	NULL
values	NULL
for	NULL
1,25	NULL
(	NULL
0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
MC1288	NULL
,	NULL
and	NULL
MC1292	NULL
are	NULL
1.4	NULL
X	NULL
10	NULL
8	NULL
,	NULL
2.8	NULL
x	NULL
10~	NULL
``	NULL
``	NULL
,	NULL
and	NULL
3.4	NULL
X	NULL
10~	NULL
``	NULL
,	NULL
respectively	NULL
(	NULL
17	NULL
)	NULL
;	NULL
and	NULL
their	NULL
ED	NULL
;	NULL
,	NULL
values	NULL
are	NULL
7	NULL
X	NULL
10	NULL
~*	NULL
,	NULL
7	NULL
x	NULL
10~**	NULL
,	NULL
and	NULL
2.2	NULL
X	NULL
10	NULL
~	NULL
'	NULL
``	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Among	NULL
nine	NULL
vitamin	NULL
D	NULL
analogues	NULL
we	NULL
tested	NULL
,	NULL
the	NULL
strongest	NULL
effects	NULL
on	NULL
VDR/DRIP205	NULL
interaction	NULL
were	NULL
limited	NULL
to	NULL
three	NULL
20-epi	NULL
analogues	NULL
.	NULL

Although	NULL
some	NULL
ligands	NULL
such	NULL
as	NULL
OCT	NULL
possess	NULL
potent	NULL
antiproliferative	NULL
effects	NULL
,	NULL
they	NULL
show	NULL
similar	NULL
or	NULL
even	NULL
weaker	NULL
effects	NULL
on	NULL
DRIP	NULL
205	NULL
binding	NULL
to	NULL
VDR	NULL
as	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
indicating	NULL
that	NULL
multiple	NULL
mechanisms	NULL
may	NULL
account	NULL
for	NULL
the	NULL
biological	NULL
activities	NULL
of	NULL
different	NULL
ligands	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
pharmacokinetic	NULL
phenomena	NULL
may	NULL
lead	NULL
to	NULL
their	NULL
altered	NULL
activities	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
affinity	NULL
of	NULL
OCT	NULL
for	NULL
DBP	NULL
is	NULL
580-fold	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Lower	NULL
affinity	NULL
for	NULL
DBP	NULL
may	NULL
increase	NULL
cellular	NULL
uptake	NULL
and	NULL
thus	NULL
activity	NULL
in	NULL
target	NULL
cells	NULL
.	NULL

A	NULL
second	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
existence	NULL
of	NULL
multiple	NULL
VDR	NULL
coactivators	NULL
may	NULL
allow	NULL
target	NULL
cells	NULL
to	NULL
respond	NULL
to	NULL
different	NULL
stimuli	NULL
in	NULL
a	NULL
more	NULL
specific	NULL
manner	NULL
.	NULL

Besides	NULL
the	NULL
DRIP	NULL
complex	NULL
,	NULL
other	NULL
coactivators	NULL
,	NULL
such	NULL
as	NULL
SRC-1	NULL
,	NULL
TIF-2/GRIP-1	NULL
,	NULL
and	NULL
AIB/ACTR	NULL
have	NULL
also	NULL
been	NULL
found	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
VDR-LBD	NULL
and	NULL
enhance	NULL
VDR-mediated	NULL
transcription	NULL
in	NULL
transfection	NULL
assays	NULL
.	NULL

For	NULL
example	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
OCT	NULL
selectively	NULL
induces	NULL
VDR	NULL
to	NULL
interact	NULL
with	NULL
TIF2	NULL
but	NULL
not	NULL
with	NULL
SRC-1	NULL
or	NULL
AIBL/ACTR	NULL
(	NULL
29	NULL
)	NULL
.	NULL

How	NULL
do	NULL
different	NULL
analogues	NULL
confer	NULL
differential	NULL
effects	NULL
on	NULL
VDR	NULL
activity	NULL
?	NULL

The	NULL
most	NULL
likely	NULL
explanation	NULL
is	NULL
that	NULL
distinct	NULL
classes	NULL
of	NULL
analogues	NULL
induce	NULL
different	NULL
LBD	NULL
conformations	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
might	NULL
be	NULL
selective	NULL
for	NULL
particular	NULL
kinds	NULL
of	NULL
coactivators	NULL
.	NULL

Several	NULL
recent	NULL
LBD	NULL
crystal	NULL
structures	NULL
have	NULL
established	NULL
that	NULL
upon	NULL
ligand	NULL
binding	NULL
,	NULL
the	NULL
AF-2	NULL
helix	NULL
(	NULL
helix	NULL
12	NULL
)	NULL
undergoes	NULL
a	NULL
major	NULL
reorientation	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
overall	NULL
LBD	NULL
structure	NULL
,	NULL
forming	NULL
part	NULL
of	NULL
a	NULL
charged	NULL
clamp	NULL
that	NULL
accommodates	NULL
the	NULL
binding	NULL
of	NULL
coactivators	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
Moreover	NULL
,	NULL
the	NULL
crystal	NULL
structure	NULL
of	NULL
the	NULL
rat	NULL
«	NULL
1	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
LBD	NULL
in	NULL
complex	NULL
with	NULL
a	NULL
thyroid	NULL
hormone	NULL
agonist	NULL
indicates	NULL
that	NULL
the	NULL
AF-2	NULL
domain	NULL
contributes	NULL
to	NULL
hormone	NULL
binding	NULL
,	NULL
suggesting	NULL
a	NULL
structural	NULL
role	NULL
for	NULL
ligand	NULL
in	NULL
forming	NULL
the	NULL
active	NULL
conformation	NULL
of	NULL
the	NULL
LBD	NULL
(	NULL
32	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
estrogen	NULL
antagonists	NULL
such	NULL
as	NULL
tamoxifen	NULL
and	NULL
ralox-ifene	NULL
appear	NULL
to	NULL
alter	NULL
the	NULL
position	NULL
of	NULL
the	NULL
AF-2	NULL
helix	NULL
such	NULL
that	NULL
helix	NULL
12	NULL
occupies	NULL
space	NULL
in	NULL
the	NULL
LBD	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
as	NULL
has	NULL
been	NULL
described	NULL
for	NULL
SRC-1	NULL
,	NULL
thereby	NULL
precluding	NULL
coactivator	NULL
binding	NULL
(	NULL
27	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Alterations	NULL
in	NULL
VDR	NULL
structure	NULL
in	NULL
response	NULL
to	NULL
the	NULL
20-epi	NULL
compounds	NULL
might	NULL
result	NULL
in	NULL
a	NULL
conformation	NULL
that	NULL
preferentially	NULL
accommodates	NULL
DRIP205	NULL
(	NULL
and	NULL
therefore	NULL
the	NULL
entire	NULL
Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
DRIP	NULL
complex	NULL
)	NULL
over	NULL
other	NULL
coactivators	NULL
,	NULL
such	NULL
as	NULL
SRC-1	NULL
or	NULL
GRIP-1	NULL
.	NULL

Differential	NULL
effects	NULL
on	NULL
VDR-LBD	NULL
structure	NULL
by	NULL
analogues	NULL
relative	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
observations	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D3	NULL
versus	NULL
20-epi	NULL
analogues	NULL
result	NULL
in	NULL
unique	NULL
ligand-dependent	NULL
VDR	NULL
sensitivities	NULL
to	NULL
pro-teases	NULL
.	NULL

When	NULL
liganded	NULL
VDR	NULL
was	NULL
treated	NULL
with	NULL
trypsin	NULL
or	NULL
chy-motrypsin	NULL
,	NULL
20-epi	NULL
analog-	NULL
VDR	NULL
complexes	NULL
showed	NULL
digestion	NULL
patterns	NULL
significantly	NULL
different	NULL
from	NULL
the	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
-VDR	NULL
complex	NULL
,	NULL
indicating	NULL
the	NULL
intrinsic	NULL
alterations	NULL
in	NULL
LBD	NULL
conformation	NULL
induced	NULL
by	NULL
1,25	NULL
(	NULL
O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
versus	NULL
20-epi	NULL
analogues	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Differential	NULL
preferences	NULL
for	NULL
coactivators	NULL
may	NULL
not	NULL
be	NULL
surprising	NULL
,	NULL
given	NULL
that	NULL
GRIP-1	NULL
is	NULL
structurally	NULL
unrelated	NULL
to	NULL
DRIP205	NULL
,	NULL
except	NULL
the	NULL
requirement	NULL
of	NULL
one	NULL
of	NULL
two	NULL
LXXLL	NULL
motifs	NULL
for	NULL
interaction	NULL
with	NULL
the	NULL
LBD	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
while	NULL
an	NULL
intact	NULL
AF-2	NULL
core	NULL
is	NULL
essential	NULL
for	NULL
VDR/DRIP	NULL
binding	NULL
,	NULL
the	NULL
details	NULL
of	NULL
these	NULL
contacts	NULL
must	NULL
be	NULL
different	NULL
from	NULL
that	NULL
for	NULL
VDR/SRC-1	NULL
.	NULL

The	NULL
glutamate	NULL
residue	NULL
at	NULL
position	NULL
420	NULL
of	NULL
VDR	NULL
is	NULL
critical	NULL
for	NULL
SRC-1	NULL
binding	NULL
but	NULL
not	NULL
for	NULL
DRIP	NULL
binding	NULL
,	NULL
reflecting	NULL
subtle	NULL
but	NULL
perhaps	NULL
key	NULL
differences	NULL
between	NULL
the	NULL
mode	NULL
of	NULL
interactions	NULL
of	NULL
these	NULL
two	NULL
coactivators	NULL
with	NULL
the	NULL
LBD	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
DRIP	NULL
complex	NULL
,	NULL
and	NULL
most	NULL
likely	NULL
other	NULL
coactivators	NULL
,	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
ligand-dependent	NULL
,	NULL
VDR-mediated	NULL
transcription	NULL
which	NULL
in	NULL
turn	NULL
is	NULL
reflected	NULL
in	NULL
key	NULL
biological	NULL
responses	NULL
,	NULL
such	NULL
as	NULL
anti-proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

The	NULL
strong	NULL
correlation	NULL
between	NULL
VDR/DRIP	NULL
interactions	NULL
and	NULL
cellular	NULL
responses	NULL
to	NULL
vitamin	NULL
D	NULL
analogues	NULL
might	NULL
be	NULL
valuable	NULL
in	NULL
developing	NULL
high	NULL
throughput	NULL
methodologies	NULL
for	NULL
discovering	NULL
new	NULL
lead	NULL
vitamin	NULL
D	NULL
compounds	NULL
that	NULL
possess	NULL
highly	NULL
potent	NULL
anti-proliferative	NULL
activities	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Lise	NULL
Binderup	NULL
and	NULL
Leo	NULL
Pharmaceutical	NULL
Products	NULL
for	NULL
20-epi	NULL
compounds	NULL
,	NULL
and	NULL
Chugai	NULL
Pharmaceuticals	NULL
for	NULL
OCT.	NULL
We	NULL
also	NULL
thank	NULL
C.	NULL
Rachez	NULL
,	NULL
V.	NULL
Bromleigh	NULL
,	NULL
and	NULL
M.	NULL
Stalleup	NULL
for	NULL
reagents	NULL
,	NULL
and	NULL
G.	NULL
Farmer	NULL
and	NULL
C.	NULL
Rachez	NULL
for	NULL
constructive	NULL
comments	NULL
during	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
.	NULL

Mellany	NULL
,	NULL
E.	NULL
(	NULL
1919	NULL
)	NULL
Lancet	NULL
2	NULL
,	NULL
407-412	NULL
.	NULL

DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
(	NULL
1979	NULL
)	NULL
Harvey	NULL
Lect	NULL
.	NULL

75	NULL
,	NULL
333-379	NULL
.	NULL

Haussler	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1969	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

62	NULL
,	NULL
155-162	NULL
4	NULL
.	NULL

McDonnell	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Scott	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Kerner	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
O'Malley	NULL
,	NULL
B.	NULL
W.	NULL
,	NULL
and	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

8	NULL
,	NULL
635-644	NULL
5	NULL
.	NULL

Danielian	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
White	NULL
,	NULL
R.	NULL
,	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Parker	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
1025-1033	NULL
6	NULL
.	NULL

Blanco	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Wang	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
Tsai	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Tsai	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
O'Malley	NULL
,	NULL
B.	NULL
W.	NULL
,	NULL
Jurutka	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Ozato	NULL
,	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
1535-1539	NULL
7	NULL
.	NULL

MacDonald	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
Sherman	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Dowd	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Jefcoat	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Delisle	NULL
,	NULL
R.	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
4748-4752	NULL
8	NULL
.	NULL

Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Rose	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
222-232	NULL
9	NULL
.	NULL

Shibata	NULL
,	NULL
H.	NULL
,	NULL
Spencer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Onate	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jenster	NULL
,	NULL
G.	NULL
,	NULL
Tsai	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Tsai	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
O'Malley	NULL
,	NULL
B.	NULL
W.	NULL
(	NULL
1997	NULL
)	NULL
Recent	NULL
Prog	NULL
.	NULL

Horm	NULL
.	NULL

Res	NULL
.	NULL

52	NULL
,	NULL
141-164	NULL
10	NULL
.	NULL

Voegel	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Heine	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Tini	NULL
,	NULL
M.	NULL
,	NULL
Vivat	NULL
,	NULL
V.	NULL
,	NULL
Chambon	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Gronemeyer	NULL
,	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

17	NULL
,	NULL
507-519	NULL
11	NULL
.	NULL

Heery	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kalkhoven	NULL
,	NULL
E.	NULL
,	NULL
Hoare	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Parker	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
887	NULL
,	NULL
733-736	NULL
12	NULL
.	NULL

Rachez	NULL
,	NULL
C.	NULL
,	NULL
Lemon	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Suldan	NULL
,	NULL
Z.	NULL
,	NULL
Bromleigh	NULL
,	NULL
V.	NULL
,	NULL
Gamble	NULL
,	NULL
M.	NULL
,	NULL
Naar	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1999	NULL
)	NULL
Nature	NULL
398	NULL
,	NULL
824-828	NULL
13	NULL
.	NULL

Rachez	NULL
,	NULL
C.	NULL
,	NULL
Suldan	NULL
,	NULL
Z.	NULL
,	NULL
Ward	NULL
,	NULL
J.	NULL
,	NULL
Chang	NULL
,	NULL
C.	NULL
P.	NULL
B.	NULL
,	NULL
Burakov	NULL
,	NULL
D.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

12	NULL
,	NULL
1787-1800	NULL
14	NULL
.	NULL

Colston	NULL
,	NULL
K.	NULL
,	NULL
Colston	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Feldman	NULL
,	NULL
D.	NULL
(	NULL
1981	NULL
)	NULL
Endocrinology	NULL
108	NULL
,	NULL
1083-1086	NULL
15	NULL
.	NULL

Abe	NULL
,	NULL
E.	NULL
,	NULL
Miyaura	NULL
,	NULL
C.	NULL
,	NULL
Sakagami	NULL
,	NULL
H.	NULL
,	NULL
Takeda	NULL
,	NULL
M.	NULL
,	NULL
Konno	NULL
,	NULL
K.	NULL
,	NULL
Yamazaki	NULL
,	NULL
T.	NULL
,	NULL
Yoshiki	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
(	NULL
1981	NULL
)	NULL
Proc	NULL
.	NULL

Nof	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.	NULL
A	NULL
.	NULL

78	NULL
,	NULL
4990-4994	NULL
16	NULL
.	NULL

Honma	NULL
,	NULL
Y.	NULL
,	NULL
Hozumi	NULL
,	NULL
M.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Konno	NULL
,	NULL
K.	NULL
,	NULL
Fukushima	NULL
,	NULL
M.	NULL
,	NULL
Hata	NULL
,	NULL
S.	NULL
,	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
Deluca	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
(	NULL
1983	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

80	NULL
,	NULL
201-204	NULL
17	NULL
.	NULL

Binderup	NULL
,	NULL
L.	NULL
,	NULL
Latini	NULL
,	NULL
S.	NULL
,	NULL
Binderup	NULL
,	NULL
E.	NULL
,	NULL
Bretting	NULL
,	NULL
C.	NULL
,	NULL
Calverley	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hansen	NULL
,	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

42	NULL
,	NULL
1569-1575	NULL
18	NULL
.	NULL

Dilworth	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Calverley	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Makin	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Jones	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

47	NULL
,	NULL
987-998	NULL
19	NULL
.	NULL

Peleg	NULL
,	NULL
S.	NULL
,	NULL
Sastry	NULL
,	NULL
M.	NULL
,	NULL
Collins	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
Bishop	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
10551-10558	NULL
20	NULL
.	NULL

Ryhanen	NULL
,	NULL
S.	NULL
,	NULL
Jaaskelainen	NULL
,	NULL
T.	NULL
,	NULL
Saarela	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
and	NULL
Maenpaa	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

70	NULL
,	NULL
414-424	NULL
21	NULL
.	NULL

Liu	NULL
,	NULL
M.	NULL
,	NULL
Lee	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Cohen	NULL
,	NULL
M.	NULL
,	NULL
Bommakanti	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
l	NULL
``	NULL
lled	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26.	NULL
.	NULL

Brzozowski	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Pike	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Dauter	NULL
,	NULL
Z.	NULL
,	NULL
Hubbard	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Bonn	NULL
,	NULL
T.	NULL
,	NULL
Engstrom	NULL
,	NULL
28	NULL
.	NULL

Vitamin	NULL
D	NULL
Analogues	NULL
and	NULL
Coactivators	NULL
Genes	NULL
Dev	NULL
.	NULL

10	NULL
,	NULL
142-153	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
Lemon	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Fondell	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

17	NULL
,	NULL
1923-1987	NULL
Olsson	NULL
,	NULL
L.	NULL
,	NULL
Gullberg	NULL
,	NULL
U.	NULL
,	NULL
Ivhed	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Nilsson	NULL
,	NULL
K.	NULL
(	NULL
1983	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

48	NULL
,	NULL
5862-5867	NULL
Cheskis	NULL
,	NULL
B.	NULL
,	NULL
Lemon	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Uskokovie	NULL
,	NULL
M.	NULL
,	NULL
Lomedico	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

9	NULL
,	NULL
1814-1824	NULL
Freedman	NULL
,	NULL
L.	NULL
P.	NULL
(	NULL
1999	NULL
)	NULL
Cell	NULL
97	NULL
,	NULL
5-8	NULL
O.	NULL
,	NULL
Ohman	NULL
,	NULL
L.	NULL
,	NULL
Greene	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Gustafsson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Carlquist	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
889	NULL
,	NULL
753-758	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
Abe	NULL
,	NULL
J.	NULL
,	NULL
Sato	NULL
,	NULL
K.	NULL
,	NULL
Kobayashi	NULL
,	NULL
T.	NULL
,	NULL
Okano	NULL
,	NULL
T.	NULL
,	NULL
Tsugawa	NULL
,	NULL
N.	NULL
,	NULL
Slatoposki	NULL
,	NULL
E.	NULL
,	NULL
Brown	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Dusso	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Raisz	NULL
,	NULL
A.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
in	NULL
Vitamin	NULL
D	NULL
:	NULL
Gene	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

16845	NULL
Regulation	NULL
,	NULL
Structure-Function	NULL
Analysis	NULL
and	NULL
Clinical	NULL
Applications	NULL
(	NULL
Nor-man	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Bouillon	NULL
R.	NULL
,	NULL
Thomasset	NULL
M.	NULL
,	NULL
eds	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

289-297	NULL
,	NULL
de	NULL
Gruyter	NULL
,	NULL
New	NULL
York	NULL
Takeyama	NULL
,	NULL
K.	NULL
I.	NULL
,	NULL
Masuhiro	NULL
,	NULL
Y.	NULL
,	NULL
Fuse	NULL
,	NULL
H.	NULL
,	NULL
Endoh	NULL
,	NULL
H.	NULL
,	NULL
Murayama	NULL
,	NULL
A.	NULL
,	NULL
Kitanaka	NULL
,	NULL
S.	NULL
,	NULL
Suzawa	NULL
,	NULL
M.	NULL
,	NULL
Yanagisawa	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kato	NULL
,	NULL
S.	NULL
(	NULL
1999	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19	NULL
,	NULL
1049-1055	NULL
Nolte	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Wisely	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Westin	NULL
,	NULL
S.	NULL
,	NULL
Cobb	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Lambert	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Willson	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
Milburn	NULL
,	NULL
M.	NULL
V.	NULL
(	NULL
1998	NULL
)	NULL
Nature	NULL
895	NULL
,	NULL
137-143	NULL
Bourguet	NULL
,	NULL
W.	NULL
,	NULL
Ruff	NULL
,	NULL
M.	NULL
,	NULL
Chambon	NULL
,	NULL
P.	NULL
,	NULL
Gronemeyer	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Moras	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
875	NULL
,	NULL
377-382	NULL
Wagner	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Apriletti	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
McGrath	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
West	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Baxter	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Fletterick	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
690-697	NULL
Shiau	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Barstad	NULL
,	NULL
D.	NULL
,	NULL
Loria	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Cheng	NULL
,	NULL
L.	NULL
,	NULL
Kushner	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Agard	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
95	NULL
,	NULL
927-987	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
20-Epi	NULL
Analogues	NULL
of	NULL
1,25-Dihydroxyvitamin	NULL
D3	NULL
Are	NULL
Highly	NULL
Potent	NULL
Inducers	NULL
of	NULL
DRIP	NULL
Coactivator	NULL
Complex	NULL
Binding	NULL
to	NULL
the	NULL
Vitamin	NULL
D	NULL
3	NULL
Receptor	NULL
Wen	NULL
Yang	NULL
and	NULL
Leonard	NULL
P.	NULL
Freedman	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:16838-16845.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.24.16838	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/24/16838	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
32	NULL
references	NULL
,	NULL
12	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
6838.	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

